Five Prime Therapeutics (FPRX) Tops Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ACCV
4. AZN
5. FICO
6. GMAB
7. QQQ
8. SPCX
9. APO
10. SMMT

Go back to Five Prime Therapeutics (FPRX) Tops Q3 EPS by 6c

Five Prime Therapeutics Reports Third Quarter 2015 Results and Provides Business Update

November 4, 2015 4:07 PM EST

Established license and collaboration agreement with Bristol-Myers Squibb for FPA008: $1.74 billion in upfront and milestone payments, double-digit royalties, and ability to continue development in PVNS and with Five Prime oncology candidates Expanded Immuno-Oncology Pipeline with New GITR Agonist Antibody Program

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ending September 30, 2015.

"Our... More